ArticleAnnals of internal medicine2011
Relationship between adherence to hepatitis C virus therapy and virologic outcomes: a cohort study.
Article in Annals of internal medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 4 syntheses or guidelines pooled it, 60 citations in OpenAlex.
- Facilitators of HCV treatment adherence among people who inject drugs: a systematic qualitative review and implications for scale up of direct acting antivirals.BMC public health · 2016Pooled it
- Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum.The International journal on drug policy · 2015Pooled it
- Factors influencing adherence in Hepatitis-C infected patients: a systematic review.BMC infectious diseases · 2014Pooled it
- The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis.PloS one · 2014Pooled it
- Article
- Barriers to the Treatment of Hepatitis C among Predominantly African American Patients Seeking Care in an Urban Teaching Hospital in Washington, D.C.Journal of the National Medical Association · 2021Article
- Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals.Journal of general internal medicine · 2020Observational
- Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment.Digestive diseases and sciences · 2019Article
- Platelet count is associated with sustained virological response rates in treatments for chronic hepatitis C.The Korean journal of internal medicine · 2019Article
- Direct-Acting Antivirals for Hepatitis C: Predictors of Early Discontinuation in the Real World.Journal of managed care & specialty pharmacy · 2019Article
- Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.Infectious disease clinics of North America · 2018Review
- Real world experience with pegylated interferon and ribavirin in hepatitis C genotype 1 population with favourableGastroenterology report · 2017Article
- Financial Incentives for Adherence to Hepatitis C Virus Clinical Care and Treatment: A Randomized Trial of Two Strategies.Open forum infectious diseases · 2017Article
- Introduction and Utilization of High Priced HCV Medicines across Europe; Implications for the Future.Frontiers in pharmacology · 2016Article
- Rational Design and Adaptive Management of Combination Therapies for Hepatitis C Virus Infection.PLoS computational biology · 2015Article
- Sofosbuvir for treatment of chronic hepatitis C.Hepatology international · 2015Review
- Self-efficacy and adherence to antiviral treatment for chronic hepatitis C.Journal of clinical gastroenterology · 2015Article
- The 3rd Canadian Symposium on Hepatitis C Virus: expanding care in the interferon-free era.Canadian journal of gastroenterology & hepatology · 2014Article
- "Fighting an uphill battle": experience with the HCV triple therapy: a qualitative thematic analysis.BMC infectious diseases · 2014Article
- Patient Characteristics, Safety, and Tolerability with Telaprevir Treatment for HCV in the Clinic: a Retrospective, Multicenter Study.Journal of clinical and translational hepatology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAdherence to therapy with pegylated interferon and ribavirin for hepatitis C virus (HCV) infection has been incompletely examined.
objectiveTo evaluate the relationship between adherence to HCV therapy and early and sustained virologic response, assess changes in adherence over time, and examine risk factors for nonadherence.
designRetrospective cohort study.
settingNational Veterans Affairs Hepatitis C Clinical Case Registry. PATIENTS: 5706 HCV-infected patients (genotypes 1, 2, 3, or 4) with at least 1 prescription for both pegylated interferon and ribavirin between 2003 and 2006 and HCV RNA results before and after treatment initiation. MEASUREMENTS: Adherence was calculated over 12-week intervals by using pharmacy refill data. End points included early virologic response (decrease of ≥2 log(10) HCV RNA at 12 weeks) and sustained virologic response (undetectable HCV RNA 24 weeks after the end of treatment).
resultsEarly virologic response increased with higher levels of adherence to ribavirin therapy over the initial 12 weeks (patients with HCV genotype 1 or 4, 25 of 68 [37%] with ≤40% adherence vs. 1367 of 2187 [63%] with 91% to 100% adherence [P < 0.001]; patients with HCV genotype 2 or 3, 12 of 18 [67%] with ≤40% adherence vs. 651 of 713 [91%] with 91% to 100% adherence [P < 0.001]). Among patients with HCV genotype 1 or 4, sustained response increased with higher adherence to ribavirin therapy over the second, third, and fourth 12-week intervals. Results were similar for adherence to interferon therapy. Mean adherence to therapy with interferon and ribavirin decreased by 3.4 and 6.6 percentage points per 12-week interval, respectively (P for trend < 0.001 for each drug). Patients who received growth factors or thyroid medications during treatment had higher mean adherence to antiviral therapy. LIMITATION: This was an observational study without standardized timing for outcome measurements.
conclusionEarly and sustained virologic responses increased with higher levels of adherence to interferon and ribavirin therapy. Adherence to therapy with both antivirals decreased over time, but more so for ribavirin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.